Cognitive Rehabilitation for Schizophrenia and Depression
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how cognitive interventions can help people with schizophrenia and depression improve their thinking skills. It focuses on enhancing verbal memory and emotion control, which often challenge individuals with these conditions. Participants will receive either the cognitive intervention (also known as cognitive training, cognitive therapy, or cognitive remediation) or join an active control group. People diagnosed with schizophrenia, schizoaffective disorder, or major depression disorder, who have been on stable medication for over a month, might be a good fit. As an unphased trial, this study offers a unique opportunity to contribute to understanding cognitive interventions and their potential benefits for mental health.
Will I have to stop taking my current medications?
The trial requires that your medication be stable for more than one month, and you cannot be taking medications with a high anticholinergic burden or benzodiazepines daily. If your current medications meet these criteria, you may not need to stop them.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that treatments aimed at improving thinking skills for people with schizophrenia and depression are generally easy to handle. In one study, more than half of the participants completed their therapy sessions as planned, indicating that many find the treatment manageable. Another study found that computer-based versions of these therapies led to small to moderate improvements in attention, memory, and depression symptoms. These results suggest minimal side effects, as participants continued with the therapy and experienced some benefits. Overall, these treatments appear to be safe and manageable options for enhancing thinking skills in these conditions.12345
Why are researchers excited about this trial?
Researchers are excited about the Cognitive Intervention for schizophrenia and depression because it offers a fresh approach beyond the typical medication and therapy options. Unlike standard treatments, which often focus on managing symptoms through pharmaceuticals like antipsychotics and antidepressants, this intervention works by enhancing cognitive functions directly. This method targets improving memory, attention, and problem-solving skills, potentially leading to better overall functioning and quality of life for patients. By focusing on cognitive rehabilitation, this treatment could provide a more holistic improvement, addressing not just symptoms but the cognitive deficits that can hinder day-to-day living.
What evidence suggests that this trial's treatments could be effective for schizophrenia and depression?
Research has shown that cognitive exercises, which participants in this trial may receive as part of the Cognitive Intervention arm, can help people with schizophrenia and depression. These exercises improve thinking skills and everyday functioning, which are crucial for daily life. One study involving 4,594 people found significant improvements in various cognitive areas. These benefits were immediate and persisted over time, suggesting that cognitive exercises could address the thinking and memory problems associated with these conditions. Meanwhile, the Active Control Intervention arm will serve as a comparator in this trial to evaluate the specific effects of the Cognitive Intervention.678910
Who Is on the Research Team?
Synthia Guimond, PhD
Principal Investigator
Royal Ottawa Mental Health Centre
Are You a Good Fit for This Trial?
This trial is for adults aged 18-45 with schizophrenia, schizoaffective disorder, or major depression who have been on stable medication for over a month. Participants must have an IQ above 70 and be fluent in English. It's not suitable for those with cognitive impairments from medical conditions, under guardianship due to decisional incapacity, MRI contraindications, recent substance abuse, or taking certain anticholinergic or daily benzodiazepine medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete baseline assessments including cognitive and social functioning tests
Treatment
Participants undergo cognitive tasks and fMRI scans to assess brain activity and cognitive function
Follow-up
Participants are monitored for changes in cognitive and social functioning post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- Active Control Intervention
- Cognitive Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Royal Ottawa Mental Health Centre
Lead Sponsor